Biobot Analytics was born at MIT

Our technology generates public health data that is naturally anonymized yielding unprecedented insight into the health of communities without collecting personal identifiable information.

Publications

August
2020

Mapping Community Opioid Exposure Through Wastewater-Based Epidemiology as a Means to Engage Pharmacies in Harm Reduction Efforts

Preventing Chronic Disease - Claire Duvallet et al.

July
2020

SARS-CoV-2 titers in wastewater are higher than expected from clinically confirmed cases

mSystems - Fuqing Wu et al.

July
2020

SARS-CoV-2 titers in wastewater foreshadow dynamics and clinical presentation of new COVID-19 cases

medRxiv - Fuqing Wu, Amy Xiao, and Jianbo Zhang et al.

Jan
2020

Rapid assessment of opioid exposure and treatment in cities through robotic collection and chemical analysis of wastewater

Journal of Medical Toxicology - Noriko Endo et al.

Sep
2019

24-hour multi-omics analysis of residential sewage reflects human activity and informs public health

bioRxiv - Mariana Matus et al.

Read more on our blog

September
2020

Mining wastewater data to refine COVID-19 case estimation

Medium - BIOBOT ANALYTICS

July
2020

Wastewater data can predict coronavirus cases

Medium - BIOBOT ANALYTICS

Apr
2020

How many people are infected with Covid-19? Sewage suggests that number is much higher than officially confirmed

Medium - BIOBOT ANALYTICS

Apr
2020

What makes a good wastewater-based epidemiology target?

Medium - BIOBOT ANALYTICS

Apr
2020

Testing for COVID-19 beyond the clinic: using wastewater epidemiology to proactively detect outbreaks

Medium - BIOBOT ANALYTICS

Wastewater-based epidemiology is a promising approach for proactive outbreak monitoring.

Wastewater epidemiology was first pioneered in Israel, Europe, and Australia by various academic research collaborations and has been demonstrated as an early warning system for poliovirus. Currently, the most well-known group is the European SCORE network, which is sponsored by the European Union to measure country-level drug consumption across the EU. Developed in the United States at MIT, our methods build on top of this body of work allowing this technology to be commercialized for the first time. Our Co-founder and CEO developed this scientific innovation during her PhD work at MIT, and is one of a few experts in the United States in this scientific field.

Our system differs from prior work in three important ways:

Sub-city level geographic resolution

We collect our samples at manholes in the city and wastewater treatment facilities. This approach enables direct measurement of metabolites, viruses, and bacteria excreted by humans.

Near-real time

We're built to deliver results in a 3-day turnaround time. This is possible because we are dedicated full-time to delivering an efficient service through automation technology.

Chemical and biological capabilities

Our system can measure drug consumption, infectious disease outbreaks, antibiotic resistance, nutrition, and exposure to environmental contaminants in populations creating a holistic early warning system for public health crises.

Biobot